Silence Therapeutics plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $559.0K | $43.3M | $31.6M | $21.7M |
| Cost of Revenue | $215.0K | $11.8M | $12.9M | $13.5M |
| Gross Profit | $344.0K | $31.4M | $18.8M | $8.2M |
| Gross Margin | 61.5% | 72.7% | 59.3% | 37.8% |
| Operating Expenses | ||||
| Research & Development | $67.8M | $67.9M | $56.9M | $43.6M |
| SG&A Expense | $22.3M | $26.9M | $26.2M | $25.7M |
| Operating Income | $-91.1M | $-63.3M | $-64.4M | $-61.0M |
| Operating Margin | -16,292.8% | -146.4% | -203.5% | -281.9% |
| Interest Expense | — | — | — | — |
| Pretax Income | $-88.6M | $-44.5M | $-53.3M | $-49.6M |
| Income Tax Expense | $11.0K | $845.0K | $956.0K | $688.0K |
| Net Income | $-88.6M | $-45.3M | $-54.2M | $-50.3M |
| Net Margin | -15,851.9% | -104.7% | -171.4% | -232.4% |
| EPS (Basic) | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| EPS (Diluted) | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| Shares Outstanding (Basic) | 141.7M | 138.8M | 111.3M | 96.6M |
| Shares Outstanding (Diluted) | 141.7M | 138.8M | 111.3M | 96.6M |
| Dividends Per Share | — | — | — | — |